Pharmacy Times
APRIL 7, 2024
Data for generalized anxiety disorders and cannabis use is scarce, but pharmacists can help educate patients on potential benefits and risks of cannabis usage.
STAT
APRIL 7, 2024
SAN DIEGO — Cancer cases among younger people have been rising for years, a trend researchers have struggled to explain. New evidence suggests a significant factor: younger generations seem to be aging faster at the cellular level than their predecessors. A team of scientists at Washington University in St. Louis tracked data from nearly 150,000 people between the ages of 37 and 54 in the U.K.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
APRIL 7, 2024
Potential adjunctive and novel treatment options based on a patient's specific symptoms and clinical factors are being explored to treat treatment-resistant schizophrenia
STAT
APRIL 7, 2024
SAN DIEGO — For decades, the Food and Drug Administration’s accelerated approval pathway has helped companies get drugs for serious unmet medical needs to patients — and the market — sooner. But about half of cancer drugs approved via this route fail to improve patient survival or quality of life in subsequent clinical trials after more than five years of follow-up , according to new findings presented Sunday at the American Association for Cancer Research annual meet
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacy Times
APRIL 7, 2024
Developments in glycine transporter type 1 inhibitors, D-amino acid oxidase inhibitors, and phosphodiesterase inhibitors are pushing schizophrenia research forward.
STAT
APRIL 7, 2024
A new analysis published Sunday challenges the clinical trial endpoint the cancer screening firm Grail is using to evaluate its blood test aimed at simultaneously detecting multiple types of tumors early. Grail’s test, called Galleri, is available in the U.S. but not yet approved by the Food and Drug Administration or reimbursed by Medicare except as part of a particular clinical trial.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
APRIL 7, 2024
A controversial heart pump from Abiomed reduced the number of deaths in severe heart attack patients, according to a highly anticipated randomized trial presented at the American College of Cardiology conference and published in the New England Journal of Medicine on Sunday. The trial, which took 10 years to enroll, followed 355 patients for 180 days in Denmark, Germany, and the United Kingdom who came into the hospital with a heart attack and dangerously low blood flow, known as cardiogenic sho
Pharmacy Times
APRIL 7, 2024
The results further confirm earlier findings from the EMPA-KIDNEY trial.
Fierce Pharma
APRIL 7, 2024
Last year closed with a flurry of big-money biopharma deals. Of the industry’s top 10 acquisitions, six came in the fourth quarter. | Market research by McKinsey found that smaller, strategic M&A deals provide greater shareholder returns than multibillion-dollar acquisitions. Analysts from McKinsey and Project Farma explain why and offer advice on how to optimize deals.
STAT
APRIL 7, 2024
ATLANTA — Beta blockers are a mainstay in cardiovascular treatment, frequently given to patients after heart attacks. But a new large trial turns that convention on its head, suggesting that the drugs may not in fact help many of these patients. The trial, which enrolled about 5,000 patients who specifically had preserved ejection fraction after a heart attack, found that long-term treatment with beta blockers did not significantly reduce the combined risk of death or new heart attack, ac
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
APRIL 7, 2024
FDA approves earlier use of J&J's BCMA CAR-T therapy Carvykti and BMS' rival Abecma for earlier use in multiple myeloma
STAT
APRIL 7, 2024
ATLANTA — New trial results show that a drug candidate from Alnylam Pharmaceuticals can lead to long-lasting blood pressure reduction when taken with certain commonly used pills, but some doctors are questioning how much the drug would actually be used in clinical practice. Zilebesiran, a novel RNA interference drug dosed every six months, is intended to address a long-standing problem: despite the availability of cheap pills to lower blood pressure, there are still high rates of uncontro
Pharmacy Times
APRIL 7, 2024
Expert perspective on current research, treatment approaches, and clinical considerations for pharmacologic management of borderline personality disorder
PharmExec
APRIL 7, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Med Ed 101
APRIL 7, 2024
For approximately 40 years, botulinum toxin has been used to treat various neuromuscular disorders, but it is not without risk. After all, the risk is in the name (botulinum toxin) and is often enough to make providers and patients wary of tapping into the therapeutic benefits of botulinum toxin. In this article, we will share […] The post What Pharmacists Should Know About Botox appeared first on Med Ed 101.
Therapeutics Education Collaboration
APRIL 7, 2024
In episode 570, James and Mike finish their trilogy on statistics. We take what we discussed in the previous podcasts and go through a couple of examples that will hopefully solidify what all the terms and numbers really mean. Show Notes 1) Sensible Medicine Doing statistics can be difficult but understanding them can be fairly simple 2) Analysis of 567,758 randomized controlled trials published over 30 years reveals trends in phrases used to discuss results that do not reach statistical signifi
Expert insights. Personalized for you.
158 
Let's personalize your content